Joint Venture16 Jun 2025, 10:51 am
Lupin and Sino Universal Pharmaceuticals Sign License and Supply Agreement for Tiotropium DPI in China
AI Summary
Global pharma major Lupin Limited has signed a license and supply agreement with Sino Universal Pharmaceuticals for the commercialization of Tiotropium Dry Powder Inhaler in the Chinese market. The agreement allows Sino Universal Pharmaceuticals to obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be responsible for manufacturing the product. This partnership aims to expand Lupin's footprint in China, ensuring timely access to innovative and high-quality healthcare solutions for patients with respiratory conditions.
Key Highlights
- Lupin and Sino Universal Pharmaceuticals sign a license and supply agreement for Tiotropium DPI in China.
- Sino Universal Pharmaceuticals to obtain regulatory approvals for selling Tiotropium DPI in China.
- Lupin to be the marketing authorization holder and responsible for manufacturing of the product.
- Partnership aims to expand Lupin's footprint in China and improve access to high-quality healthcare solutions.
- Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions.